InMode Newsroom

InMode Faces Macroeconomic Challenges and Manufacturing Disruptions, Leading to Hold Rating

TipRanksJan 10 21:07

Barclays Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $26

Futu NewsJan 10 18:34

InMode Is Maintained at Overweight by Barclays

Dow JonesJan 9 19:49

InMode Analyst Ratings

BenzingaJan 9 19:40

Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $26

Futu NewsJan 9 07:32

Needham Maintains InMode(INMD.US) With Hold Rating

Futu NewsJan 8 23:33

Needham Remains a Hold on InMode (INMD)

TipRanksJan 8 22:38

BTIG Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $25

Futu NewsJan 8 22:31

Analysts Offer Insights on Healthcare Companies: InMode (INMD) and Sana Biotechnology (SANA)

TipRanksJan 8 22:13

UBS Adjusts Price Target on InMode to $19 From $17, Maintains Neutral Rating

MT NewswiresNov 1, 2024 22:00

InMode Analyst Ratings

BenzingaOct 31, 2024 18:04

Needham Maintains InMode(INMD.US) With Hold Rating

Futu NewsOct 31, 2024 03:33

InMode Initiated at Buy by BTIG

Dow JonesOct 17, 2024 18:17

BTIG Initiates InMode(INMD.US) With Buy Rating, Announces Target Price $25

Futu NewsOct 17, 2024 04:33

InMode's Strategic Growth Potential and Market Positioning: A Buy Recommendation by Marie Thibault

TipRanksOct 17, 2024 04:27

InMode Is Maintained at Overweight by Barclays

Dow JonesOct 14, 2024 22:31

Barclays Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $27

Futu NewsOct 14, 2024 16:32

Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $27

Futu NewsOct 12, 2024 21:31

Baird Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $22

Futu NewsOct 12, 2024 04:31

UBS Maintains InMode(INMD.US) With Hold Rating, Cuts Target Price to $17

Futu NewsOct 11, 2024 14:32